United States Antipeptic Ulcer Drugs Market is expected to reach US$ 6.26 Billion by 2033 | Top 3 key players - AstraZeneca, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceuticals.

Market Size and Growth:

The Global Antipeptic Ulcer Drugs Market size reached US$ 4.56 Billion in 2023 with a rise of US$ 4.70 Billion in 2024 and is expected to reach US$ 6.26 Billion by 2033, growing at a CAGR of 3.2% during the forecast period 2025-2033. The Market is growing due to the rising prevalence of gastrointestinal disorders, increasing awareness about digestive health, and the adoption of advanced drug therapies for ulcer treatment.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/antipeptic-ulcer-drugs-market?sz

The Antipeptic Ulcer Drugs Market encompasses the global trade and development of medications designed to prevent and treat peptic ulcers, including proton pump inhibitors, H2 receptor antagonists, and antacids. These drugs reduce gastric acid production, protect the stomach lining, and promote ulcer healing. Market growth is driven by rising gastrointestinal disorders, aging populations, lifestyle changes, and increased healthcare awareness.

Industry Recent Developments:

United States:

✅ Drug pipeline advancements: Takeda Pharmaceuticals is progressing in Phase 3 clinical trials with Vonoprazan fumarate, a potassium-competitive acid blocker (P-CAB) aimed at peptic ulcer treatment (October 2025).

✅ Rising R&D and government support: Increasing focus on research and government policies supporting development has accelerated new drug launches and combination therapies for peptic ulcer disease (October 2025).

✅ Market growth drivers: The US market was valued at USD 2.5 billion in 2024 and is projected to grow steadily, driven by the prevalence of Helicobacter pylori infections and growing adoption of triple therapy (September 2025).

Japan:

✅ New product launch: In June 2025, Eisai Co., Ltd. launched "Pariet® S," the first proton pump inhibitor approved as an over-the-counter drug in Japan to relieve severe heartburn and acid reflux symptoms (June 2025).

✅ Market growth and demographics: Japan's antipeptic ulcer drugs market is expanding due to the aging population, changing dietary habits, and increased healthcare awareness, with a forecast CAGR of around 4.4% over 2023-2033 (September 2025).

✅ Technological and pharmaceutical advances: Japan continues to be a frontrunner in producing innovative drugs for peptic ulcer treatment, evidenced by steady growth in the market and focus on novel drug delivery systems and combination therapies (August 2025).

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/antipeptic-ulcer-drugs-market?sz

Major 5 Key Players:

1. AstraZeneca
Overview: AstraZeneca is a global biopharmaceutical company with a strong presence in the gastrointestinal (GI) segment.

Key Products: While AstraZeneca is renowned for its oncology and cardiovascular drugs, it also offers treatments for GI disorders, including peptic ulcers.

Strategic Initiatives: The company has been expanding its U.S. operations, investing $50 billion, and plans to launch 20 new medicines by 2030. In Q2 2025, AstraZeneca reported strong revenue growth, driven by robust U.S. demand and rising sales of newer drugs.

2. Sun Pharmaceutical Industries Ltd.
Overview: Sun Pharma is India's largest pharmaceutical company and a significant player in the global market.

Key Products: Sun Pharma offers a range of generic drugs for treating peptic ulcers, including proton pump inhibitors (PPIs) and H. pylori eradication therapies.

Market Position: The company has a strong presence in over 50 countries and has been focusing on chronic therapies, contributing to its growth.

3. Takeda Pharmaceuticals
Overview: Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.

Key Products: Takeda offers treatments for various GI disorders, including peptic ulcers, with a focus on proton pump inhibitors and H. pylori eradication therapies.

Strategic Initiatives: The company has been focusing on expanding its portfolio in the GI segment to address the growing demand for peptic ulcer treatments.

4. Pfizer Inc.
Overview: Pfizer is one of the world's premier biopharmaceutical companies, known for its innovative therapies.

Key Products: Pfizer offers a range of treatments for peptic ulcers, including proton pump inhibitors and H. pylori eradication therapies.

Market Position: The company has a strong presence in North America, which accounted for a significant share of the global peptic ulcer drugs market in 2019.

5. Torrent Pharmaceuticals Ltd.
Overview: Torrent Pharmaceuticals is a leading Indian pharmaceutical company with a growing global presence.

Key Products: The company offers a variety of generic drugs for treating peptic ulcers, including proton pump inhibitors and H. pylori eradication therapies.

Market Position: As of June 2025, Torrent Pharma became India's 5th largest drugmaker, reflecting its strong performance and expanding influence in the global pharmaceutical landscape.

FDA Approvals and Regulatory Updates:

Famotidine Injection (NDA 219935): Approved for hospitalized adults and pediatric patients aged 1 year and older for the treatment of active duodenal and gastric ulcers, symptomatic nonerosive gastroesophageal reflux disease (GERD), erosive esophagitis due to GERD, pathological hypersecretory conditions, and reduction of duodenal ulcer recurrence.

Robinul (Glycopyrrolate) Injection (NDA 17558/S-068): The FDA approved a supplemental new drug application to update the prescribing information, specifying that Robinul Injection is not indicated as monotherapy for the treatment of peptic ulcer due to insufficient evidence for ulcer healing. F

Mergers, Acquisitions, and Strategic Partnerships:

RedHill Biopharma and Cumberland Pharmaceuticals: Entered into a U.S. co-commercialization agreement for Talicia®, a treatment for Helicobacter pylori infection and duodenal ulcers. The partnership includes equal sharing of net revenues and joint marketing efforts.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=antipeptic-ulcer-drugs-market

Segments Covered in the Antipeptic Ulcer Drugs Market: CCC

1. By Drug Type
The market is classified based on the type of drugs used to treat peptic ulcers:

Proton Pump Inhibitors (PPIs):
Reduce stomach acid production by blocking proton pumps. Widely prescribed due to high efficacy.
Examples: Omeprazole, Esomeprazole.

H2-Receptor Antagonists (H2RAs):
Decrease acid production by blocking histamine receptors in the stomach lining.
Examples: Ranitidine, Famotidine.

Antacids:
Neutralize stomach acid to provide quick relief from ulcer symptoms.
Examples: Magnesium hydroxide, Aluminum hydroxide.

Cytoprotective Agents:
Protect the stomach lining from acid damage and promote healing.
Examples: Sucralfate, Misoprostol.

Combination Drugs:
Include combinations like antibiotics + PPIs to treat H. pylori-induced ulcers.

2. By Route of Administration
Classifies the drugs by how they are delivered to patients:

Oral: Tablets, capsules, liquids - most common and convenient.

Intravenous (IV): Used for severe cases or hospitalized patients.

3. By Distribution Channel
Categorizes the market based on how drugs reach patients:

Hospital Pharmacies: Major channel for inpatient treatment.

Retail Pharmacies: Over-the-counter and prescription drugs for outpatients.

Online Pharmacies: Growing due to convenience and telemedicine trends.

4. By End-User
Identifies the primary users of the drugs:

Hospitals & Clinics: Patients with acute or chronic ulcers.

Homecare/Outpatients: Patients managing ulcers with prescribed or OTC medications.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Antipeptic Ulcer Drugs Market in 2025?
◆ What is the projected growth rate of the Antipeptic Ulcer Drugs Market through 2033?
◆ Who are the key players in the Antipeptic Ulcer Drugs Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.